Page 62 - ஜாக்கக்ஸ் ஒருமித்த கருத்து மதிப்பீடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share: Moderna (NASDAQ: MRNA) saw its stock jump on Thursday despite mounting losses, after the COVID-19 vaccine-maker reported more than double the revenue Wall Street predicted. Moderna missed EPS expectations with revenue far surpassing analyst forecasts as the company first began to recognize revenue from sales of its COVID-19 vaccine in December 2020. The loss was simply a result of heavy investment to increase the production of its COVID-19 vaccine. The company has spent the past two months producing and shipping its much-awaited coronavirus vaccine but its fourth-quarter is merely the surface of its vaccine success. In 2021, Moderna plans to manufacture 600-700 million doses of its COVID-19 vaccine but it should be able to expand its capacity to 1.4 billion doses in 2022 due to heavy capital investments, all of which should result in massive profits.

South africaSouth africanStephane bancelBiomedical advanced researchDevelopment authorityWall streetZacks consensus estimateEmergency use authorizationExecutive stephane bancelவளர்ச்சி அதிகாரம்சுவர் தெருஜாக்கக்ஸ் ஒருமித்த கருத்து மதிப்பீடுஅவசரம் பயன்பாடு அங்கீகாரம்